Duofilm Liquid
Texto original en francés.
Producto de salud natural autorizado en Canadá
- Titular
- Haleon US Holdings LLC
- NPN o DIN-HM
- 00370576
- Estado
- Licencia no activa
- Fecha de licencia
- 30 de noviembre de 2009
- Fecha de revisión
- 21 de febrero de 2017
- Forma
- Solution semblabe au collodion.
- Vía de administración
- Topique
- Tipo de solicitud
- DIN de transition
El análisis de dosis orales no se aplica sin una vía exclusivamente oral establecida.
Composición
| Ingrediente medicinal y fuente | Por unidad posológica, según la fuente |
|---|---|
| Acide lactique | 16,7 % |
Ingredientes no medicinales
Flexible collodion
Dosis recomendadas en Canadá
| Población | Edad | Cantidad por toma | Frecuencia |
|---|---|---|---|
| Sous-population S/O | Non précisée | 1 Goutte(s) | 24 heures |
Usos autorizados en Canadá
For the removal of common warts.
Texto original en inglés.
Un uso autorizado en Canadá no es una declaración de propiedades saludables autorizada en la Unión Europea. Consulte el registro de declaraciones de propiedades saludables.
Advertencias en Canadá
Cautions and Warnings : DUOFILM® is for external use only. DUOFILM® is extremely flammable and should be kept away from fire or flame. Keep bottle tightly capped when not in use. Store at controlled room temperature away from heat. Patients should be advised not to inhale the vapour. DUOFILM® may cause eye irritation. Avoid contact with eyes and other mucous membranes. In case of accidental contact with the eyes or other mucous membranes, flush with water for 15 minutes. If discomfort persists, patients should be advised to contact a physician. Avoid exposure to healthy skin. DUOFILM® may cause skin irritation. If undue skin irritation develops, treatment should be discontinued and patients should be advised to contact a physician or pharmacist. Consider alternative treatments if warts cover a large area of the body (more than 5 cm²) due to the potential risk of salicylate toxicity. DUOFILM® is not recommended in patients with peripheral neuropathy except under the supervision of a physician. Oral salicylates taken during or immediately after a viral illness have been associated with Reye's syndrome and hence there is a theoretical risk with topical salicylates. Therefore, do not use in children or teenagers during or immediately after chickenpox, influenza, or other viral infections. It has been reported that salicylates are excreted via breast milk. Patients should be advised to consult a health care physician if discomfort persists. Keep out of the sight and reach of children. Pregnancy and Lactation Pregnancy The safety of DUOFILM® during human pregnancy has not been established. Studies in animals given salicylic acid orally demonstrated embryo-toxicity at high doses. DUOFILM® is not recommended during pregnancy. Lactation Salicylates are excreted in human milk. DUOFILM® is not recommended during lactation. If used or administered during lactation, care should be taken to avoid contact with the breast area in order to avoid accidental ingestion by the infant.
Texto original en inglés.
Known Adverse Reactions : Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: very common (greater than and or equal to 1/10), common (greater than and or equal to 1/100 to less than 1/10), uncommon (greater than and or equal to 1/1000 to less than 1/100) rare (greater than and or equal to 1/10000 to less than 1/1000) and very rare (less than 1/10000). Clinical Trial Data Immune system disorders Common: Rash Skin and subcutaneous tissue disorders Very common: Application site reaction, pruritus, burning sensation, erythema, scaling, dryness Common: Skin hypertrophy Post-marketing data Immune system disorders Rare: Application site hypersensitivity including inflammation Skin and subcutaneous tissue disorders Rare: Application site pain and irritation. Application site discoloration/skin discoloration. Exposure to healthy skin can lead to application site blistering and skin exfoliation. Allergic dermatitis. Interactions DUOFILM® may increase the absorption of other topically applied medicines. Therefore, concomitant use of DUOFILM® and other topical medicines on the treated area should be avoided.
Texto original en inglés.
Fuente
Ficha oficial de Health Canada, licencia 00370576
Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias, consultado el 27 de octubre de 2026.
Contient des informations visées par la Licence du gouvernement ouvert – Canada (Santé Canada, BDPSNH)
Texto original en francés.
Texto original en francés.
La fórmula vendida en Europa con el mismo nombre puede ser diferente. Esta información no sustituye el consejo de un médico o farmacéutico.
Lista en la revisión oficial del (registro: Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias).